Related Experiment Video
Updated: Jan 1, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience
Ninna Aggerholm-Pedersen1, Phillip Rossen1, Hanne Rose1
1Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Background:
The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy.
Methods:
All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed.
Results:
Nineteen patients were identified. The median age was 38 years (range 18-62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity.
Conclusion:
Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed.
Insights
Pazopanib shows effectiveness in treating metastatic bone sarcomas, offering improved survival and stable disease in patients resistant to standard chemotherapy. This targeted therapy was generally well-tolerated, indicating its potential as a new treatment option.
Area of Science:
- Oncology
- Pharmacology
- Medical Research
Background:
- Metastatic bone sarcomas have a poor prognosis with limited chemotherapy effectiveness.
- Novel therapeutic strategies are crucial for improving outcomes in these patients.
- Pazopanib, a tyrosine kinase inhibitor, has demonstrated efficacy in metastatic soft tissue sarcomas.
Purpose of the Study:
- To evaluate the off-label efficacy of pazopanib in metastatic bone sarcoma patients.
- To assess pazopanib's impact on survival outcomes in refractory bone sarcoma cases.
- To determine the tolerability and safety of pazopanib in this patient population.
Main Methods:
- Retrospective analysis of 19 metastatic bone sarcoma patients treated with pazopanib.
- Data collection included demographics, treatment details, and survival outcomes.
- Evaluation period: October 2011 to October 2017 at Aarhus University Hospital.
Main Results:
- Median overall survival was 11 months; median progression-free survival was 5.4 months.
- 68% of patients achieved partial response or stable disease.
- Pazopanib was generally well-tolerated, with dose reductions in 5 patients due to toxicity.
Conclusions:
- Off-label pazopanib demonstrates effectiveness and tolerability in metastatic bone sarcomas of various histologies.
- Pazopanib represents a promising treatment option for refractory bone sarcomas.
- Further research is warranted to explore pazopanib's efficacy alone or in combination therapies.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...